eligibility_summary
Include: ≤18y high‑risk R/R neuroblastoma, PS ≥50, post standard tx, ≥12‑wk survival, recovered from prior therapy with washouts, adequate labs, consent/comply. Exclude: symptomatic brain mets, major cardiac disease or ILD, bleeding/clots, recent major surg/trauma, GI fistula/perf, proteinuria, symptomatic effusions, active infxn, recent trials, steroids/immunosupp or autoimmune, IL‑2 contraindication, live vaccines, other malignancy, HBV/HCV/HIV+, prior allo transplant, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Ex vivo expanded and activated umbilical cord blood–derived natural killer (NK) cells (biological, adoptive cellular immunotherapy), administered in multiple infusions with background therapies (anti-GD2 monoclonal antibody and chemotherapy). Mechanism: allogeneic NK cells recognize neuroblastoma via missing‑self and stress ligands and kill through perforin/granzyme release and death‑receptor signaling, with anti‑GD2, they drive FcγRIIIa (CD16)–mediated ADCC. Targets: GD2‑positive neuroblastoma cells, NK activation/inhibition pathways (e.g., NKG2D, DNAM‑1, KIR–HLA balance) and the CD16‑ADCC axis.